 <h1>Veklury Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>remdesivir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about remdesivir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Veklury.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to remdesivir: parenteral powder for injection for iv infusion, parenteral solution concentrate for injection for iv infusion</i></p><p>Side effects include:</p><p>Adverse effects reported in ≥5% of patients receiving remdesivir (the active ingredient contained in Veklury) include nausea and increased ALT and AST concentrations. </p><p>Phase 3, adaptive, randomized, placebo-controlled trial in hospitalized adults with mild/moderate or severe COVID-19 (NCT04280705; ACTT-1): Serious adverse events reported in 51% of patients in remdesivir group and 57% in placebo group.  Adverse events leading to discontinuance of treatment reportedly occurred in 2% of patients receiving remdesivir (seizure, infusion-related reactions, increased aminotransferase concentrations, decreased GFR, acute kidney injury) and 3% of those receiving placebo. </p><p>Phase 3, randomized, open-label trial in hospitalized adults with severe COVID-19 (NCT04292899; GS-US-540-5773; SIMPLE-Severe): Adverse events reported in 70 or 74% of patients who received a 5- or 10-day remdesivir regimen, respectively; serious adverse events (e.g., respiratory distress or failure, septic shock) reported in 21 or 35%, respectively, and grade 3 or greater adverse events reported in 30 or 43%, respectively.  Drug discontinued because of adverse events in 4% of patients in 5-day group and 10% of patients in 10-day group.  Most common adverse events overall were nausea (10 or 9%), acute respiratory failure (6 or 11%), increased ALT concentrations (6 or 8%), and constipation (7% in both groups), </p><p>Phase 3, randomized, open-label trial in hospitalized adults with moderate COVID-19 (NCT04292730; GS-US-540-5774; SIMPLE-Moderate): Adverse events reported in 51 or 59% of patients who received a 5- or 10-day remdesivir regimen, respectively;  serious adverse events reported in 5% of patients in both treatment groups, and grade 3 or greater adverse events reported in 11 or 12% of patients receiving 5- or 10-day regimen, respectively.  Most common adverse events in patients receiving these respective regimens were nausea (10 or 9%), diarrhea (6 or 5%), hypokalemia (5 or7%), and headache (5% in both treatment groups).  Four patients (2%) in 5-day group and 8 patients (4%) in 10-day group discontinued remdesivir due to an adverse event. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to remdesivir: intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>The most common side effect in healthy subjects was increased transaminases.  The most common side effects in patients with coronavirus disease 2019 (COVID-19) were nausea, increased AST, and increased ALT.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In studies in healthy subjects, increases in ALT, AST, or both in those who received this drug were grade 1 (10%) or grade 2 (4%).  In a clinical study of patients with COVID-19, the incidence of at least grade 3 nonserious side effects of increased aminotransferase levels (including ALT, AST, or both) was 4% with this drug compared to 6% with placebo.  In a clinical trial in hospitalized patients with severe COVID-19 receiving this drug for 5 or 10 days, any grade (at least 1.25 times the upper limit of normal [1.25 x ULN]) laboratory abnormalities of increased AST and increased ALT were reported in 40% and 42% of patients, respectively; at least grade 3 (at least 5 x ULN) laboratory abnormalities of increased AST and increased ALT were both reported in 7% of patients.  In a clinical trial in hospitalized patients with moderate COVID-19 receiving this drug for 5 or 10 days compared to standard of care, any grade laboratory abnormalities of increased AST and increased ALT occurred in 32% and 33% of patients, respectively, receiving this drug and 33% and 39% of patients, respectively, receiving standard of care; at least grade 3 laboratory abnormalities of increased AST and increased ALT occurred in 2% and 3% of patients, respectively, receiving this drug and 6% and 7%, respectively, receiving standard of care.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased transaminases, increased ALT, increased AST</p><p><b>Common</b> (1% to 10%): Increased aminotransferase levels (including ALT, AST, or both), increased bilirubin</p><p><b>Uncommon</b> (0.1% to 1%): Increased hepatic enzyme, hypertransaminasemia, increased liver function tests<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Decreased CrCl (based on Cockcroft-Gault formula; up to 19%), decreased estimated glomerular filtration rate (eGFR; up to 18%), increased creatinine (up to 15%)</p><p><b>Uncommon</b> (0.1% to 1%): Decreased GFR, acute kidney injury<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (up to 15%), decreased lymphocytes (up to 11%)</p><p><b>Common</b> (1% to 10%): Increased prothrombin time<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased glucose (up to 12%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Seizure</p><p><b>Frequency not reported</b>: Generalized seizure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion-related reactions, increased blood alkaline phosphatase<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased heart rate<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site erythema</p><p><b>Frequency not reported</b>: Administration site extravasation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Hypersensitivity</p><p><b>Frequency not reported</b>: Anaphylaxis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,   Inc. "Canadian Product Information." O 0 (2015):</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Veklury (remdesivir)." Gilead Sciences, Foster City, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Can Remdesivir be used to treat COVID-19 (coronavirus)?</li>
</ul><h2>More about Veklury (remdesivir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: investigational drugs</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Veklury &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>COVID-19</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>